Roche ($RHHBY) is bowing out of a two-year-old collaboration with a subsidiary of a struggling Wilex. The Munich-based biotech says that Roche is backing away from their development deal on antibody-targeted amanitin conjugates as the pharma giant has been deprioritizing research deals that fall outside of immuno-oncology. Wilex's lead drug, Rencarex, failed a Phase III trial in 2012. Release